

ASX ANNOUNCEMENT

CELLMID TO RAISE UP TO \$3.8 MILLION THROUGH A RENOUNCEABLE RIGHTS ISSUE

- Cellmid to raise up to \$3.8 million through a Renounceable Rights Issue offering two (2) new shares for every five (5) shares held
- Priced at 7.5 cents per share to reward existing shareholders
- Discount of 26% to the 30 day VWAP of 10.2 cents
- With every two (2) new Shares, shareholders receive one (1) free attaching option (“New Option”)
- New Options will have an exercise price of 18 cents, a term of 2 years and the Company will apply to the ASX for the New Options to be quoted
- Shareholders can trade their rights and apply for additional shares and free attaching options
- Rights to start trading from Wednesday, 10 March 2021
- Partially underwritten for \$3 million by Mahe Capital Pty Limited (“Mahe Capital”), including sub-underwriting by Non-Executive Director Dennis Eck for \$388,878.
- All eligible Directors intend to participate
- Funds will be used to exploit Chinese distribution agreements, explore new market opportunities for the Company’s consumer health products and working capital

SYDNEY, Monday, 8 March 2021: Cellmid Limited (ASX: CDY) (“Cellmid” or “the Company”) is pleased to announce a renounceable rights issue to raise up to \$3.8 million to fund the Company's recently initiated Chinese distribution agreements¹, explore additional product and market opportunities for the Company's anti-aging beauty technologies and general working capital.

Under the offer, eligible shareholders will be offered two (2) New Shares for every five (5) shares held at 5.00pm (EST) on Thursday, 11 March 2021 (“Record Date”). For every two (2) New Shares issued, investors will receive one (1) free attaching New Option with an exercise price of \$0.18 and a term of two years from the date of issue. The Company will apply for the New Shares and New Options to be quoted on the ASX. The rights issue price represents a discount of 26% to the Company's 30 day VWAP of 10.16 cents.

On completion, the Company will be well-funded with approximately \$7.95 million of cash², which will be used to increase sales of its consumer health products into China under its distribution agreements, broaden the product portfolio, and increase digital marketing activities with the view to grow subscriber numbers. It will also allow the Company to pursue other markets for its anti-aging consumer products.

¹ ASX Announcement dated 14 December 2021 and Page 11 of the AGM Presentation dated 30 November 2021

² Based on the full \$3.8m being raised and after the costs of the Rights Issue are deducted

Cellmid's anti-aging hair care brands are currently sold in Australia, Japan, USA, China, Germany and the UK under the brands evoliss®, Jo-Ju® and Lexilis®. In addition to pursuing revenue growth from its existing markets, the Company's key objective is to achieve operational profitability for the full 2022 financial year by building a substantial direct-to-consumer business (ecommerce) and from growing revenue in China through existing distributors and new partnerships.

Initial orders have recently been shipped under the distribution agreements with Chinese distributors Ourui Health Management Limited³ and Aeon International⁴. Cellmid will continue to pursue other product and market opportunities for its own brands, while exploring potential licensing of its anti-aging technologies.

The renounceable rights issue is open to all eligible shareholders who have a registered address within Australia or New Zealand, and who hold Shares on the Record Date. The Rights Issue will close on Friday, 26 March 2021 (unless extended), and eligible shareholders can apply for shortfall in excess of their entitlement. Shareholders can also trade their rights from Wednesday, 10 March 2021 until close of trading on 19 March 2021.

Mahe Capital advised on the issue and acts as Lead Manager and Underwriter. The issue is partially underwritten to \$3 million. For their services Mahe Capital will receive a lead manager fee of \$60,000, a management fee of 1% of the total amount raised, an underwriting fee of 5% of the amount underwritten, a placement fee of 5% of any shortfall placed by Mahe Capital beyond the amount underwritten and 1 New Option for every \$2 raised.

The underwriting agreement is subject to conditions (including termination provisions) customary for a transaction of this nature, which can be read in full in section 8.4 of the Prospectus.

The underwritten amount of \$3 million includes a sub-underwriting of \$388,877.70 by Non-Executive Director, Dennis Eck. As Mr Eck is a resident of the United States he will not be eligible to participate in the Rights Issue and the amount of his sub-underwriting represents that amount that he would have been entitled to had he been resident in Australia. Mr Eck has waived any right to a sub-underwriting fee. All other Directors intend to participate for their entitlement.

All New Shares issued will rank equally with existing shares on issue and the Company will apply for quotation of the New Shares and New Options. A Prospectus in relation to the Rights Issue was lodged with ASIC on Monday, 8 March 2021 and, together with a personalised entitlement acceptance form, will be sent to eligible shareholders shortly after the Record Date.

Eligible shareholders should consider the Prospectus in deciding whether to acquire securities under the renounceable rights issue and will need to follow the instructions on

³ ASX announcement dated 14 December 2021

⁴ Page 11 of the AGM presentation dated 30 November 2021

the entitlement and acceptance form that will accompany the prospectus. The following are indicative dates in respect of the capital raising:

Event	Date
Ex entitlement date Rights trading commences on a deferred settlement basis	10 March 2021
Record Date for determining entitlements (5:00pm EST)	11 March 2021
Prospectus and personalised Entitlement and Acceptance Forms sent out to Eligible Shareholders	12 March 2021
Rights trading ends	19 March 2021
Closing date of entitlement issue (5:00pm EST)	26 March 2021
Announcement of results of issue	31 March 2021
Issue date	1 April 2021

These dates are indicative only and may change, subject to the Corporations Act and Listing Rules.

Approved for release by the Board of Directors of Cellmid.

End

Contact:

Lee Tamplin, Company Secretary

T +61 2 8072 1429

Cellmid Limited (ASX: CDY)

Cellmid is a health and beauty-tech business growing shareholder value through the development, global distribution and sales of its proprietary brands of differentiated, clinically validated longevity and anti-aging solutions. Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated products for hair, skin and body. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.